Discovery and validation of cell-free DNA methylation markers for specific diagnosis, differentiation from benign tumors, and prognosis of breast cancer
Authors:
Open Access
- 16 June 2025
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 27 (1) , 1-13
Abstract
Plasma cell-free DNA (cfDNA) methylation is emerging as a non-invasive marker for various cancers. We aimed to identify specific methylation markers for diagnosis, differentiation from benign tumors, and prognosis of breast cancer (BC), which are essential for clinical decision-making yet seldom examined together. BC-specific methylation markers were identified using an in-house 850K dataset combined with large-scale publicly available 450 or 850K datasets. Multiplex digital droplet PCR (mddPCR) assays were developed to detect methylation in cfDNA from 201 BC patients, 83 healthy donors, and 71 individuals harboring benign tumors. Diagnostic and prognostic performance were evaluated using logistic and Cox regression models, respectively. The basic mechanism of a selected gene was explored through in vitro experiments. We identified 21 BC-specific methylated CpG sites that distinguished BC from tumor-adjacent tissues with high diagnostic accuracy. In the cfDNA cohort, three mddPCR assays targeting eight markers achieved an area under the curve (AUC) of 0.856 (95% CI = 0.814–0.898) for distinguishing BC from healthy controls, and 0.742 (95% CI = 0.684–0.801) for differentiating BC from benign tumors. Notably, combining these methylation markers with mammography and ultrasound improved diagnostic performance, resulting in an AUC of 0.898 (95% CI = 0.858–0.938) for differentiating BC from benign tumors. In the TCGA-BC dataset, prognostic model based on six sites was associated with poor overall survival prognosis (hazard ratio = 2.826, 95%CI: 1.841–4.338, p < 0.0001). In vitro experiments elucidated that FAM126A overexpression regulates BC cells malignant phenotypes. Our study demonstrated potential values of methylation-based markers in the detection and prognosis of BC.Keywords
Funding Information
- Postgraduate Research and Practice Innovation Project (YJSCX2023-27HYD)
- Heilongjiang Provincial Natural Science Foundation of China (ZD2021H001)
- National Natural Science Foundation of China (82073643)
This publication has 38 references indexed in Scilit:
- Frequent loss of FAM126A expression in colorectal cancer results in selective FAM126B dependencyiScience, 2024
- Breast Cancer Incidence After a False-Positive Mammography ResultJAMA Oncology, 2024
- DNA methylation biomarkers for noninvasive detection of triple‐negative breast cancer using liquid biopsyInternational Journal of Cancer, 2022
- Whole‐genome bisulfite sequencing analysis of circulating tumour DNA for the detection and molecular classification of cancerClinical and Translational Medicine, 2022
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNAAnnals of Oncology, 2020
- A seven‐DNA methylation signature as a novel prognostic biomarker in breast cancerJournal of Cellular Biochemistry, 2019
- Performance of Screening Ultrasonography as an Adjunct to Screening Mammography in Women Across the Spectrum of Breast Cancer RiskJAMA Internal Medicine, 2019
- Head and neck squamous cell carcinoma: prediction of cervical lymph node metastasis by dual-energy CT texture analysis with machine learningEuropean Radiology, 2019
- Breast density implications and supplemental screeningEuropean Radiology, 2018
- Breast Cancer Screening With Imaging: Recommendations From the Society of Breast Imaging and the ACR on the Use of Mammography, Breast MRI, Breast Ultrasound, and Other Technologies for the Detection of Clinically Occult Breast CancerJournal of the American College of Radiology, 2010